Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

HLVX - HilleVax Inc


IEX Last Trade
1.87
-0.020   -1.070%

Share volume: 779,100
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$1.89
-0.02
-1.06%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
-3.61%
1 Month
-0.53%
3 Months
-84.58%
6 Months
-89.12%
1 Year
-86.23%
2 Year
-83.38%
Key data
Stock price
$1.87
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$1.58 - $20.22
52 WEEK CHANGE
-$0.86
MARKET CAP 
93.098 M
YIELD 
N/A
SHARES OUTSTANDING 
49.785 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$577,862
AVERAGE 30 VOLUME 
$551,529
Company detail
CEO:
Region: US
Website:
Employees: 52
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

hillevax is a biopharmaceutical company focused on the development and commercialization of novel vaccines. our initial program, hil-214, is a virus-like particle (vlp) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.

Recent news